Plants as sources of natural and recombinant anti-cancer agents |
| |
Authors: | J.F. Buyel |
| |
Affiliation: | 1. Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Forckenbeckstraße 6, 52074 Aachen, Germany;2. Institute for Molecular Biotechnology, Worringerweg 1, RWTH Aachen University, 52074 Aachen, Germany |
| |
Abstract: | Herbal remedies were the first medicines used by humans due to the many pharmacologically active secondary metabolites produced by plants. Some of these metabolites inhibit cell division and can therefore be used for the treatment of cancer, e.g. the mitostatic drug paclitaxel (Taxol). The ability of plants to produce medicines targeting cancer has expanded due to the advent of genetic engineering, particularly in recent years because of the development of gene editing systems such as the CRISPR/Cas9 platform. These technologies allow the introduction of genetic modifications that facilitate the accumulation of native pharmaceutically-active substances, and even the production heterologous recombinant proteins, including human antibodies, lectins and vaccine candidates. Here we discuss the anti-cancer agents that are produced by plants naturally or following genetic modification, and the potential of these products to supply modern healthcare systems. Special emphasis will be put on proteinaceous anti-cancer agents, which can exhibit an improved selectivity and reduced side effects compared to small molecule-based drugs. |
| |
Keywords: | Lectins Molecular farming Monoclonal antibodies Plant secondary metabolites Therapeutic anti-cancer vaccines APIs active pharmaceutical ingredients ADCC antibody-dependent cellular cytotoxicity ADCs antibody–drug conjugates ATPS aqueous two-phase systems CHO Chinese hamster ovary CDC complement-dependent cytotoxicity DoE design-of-experiments EBV Epstein–Barr virus EBA expanded-bed adsorption FDA Food and Drug Administration GMP good manufacturing practice HBsAg hepatitis B soluble antigen HBV Hepatitis B virus HCPs host cell proteins HPV Human papillomavirus ML1 mistletoe lectin 1 mAbs monoclonal antibodies NK natural killer R&D research and development PEG polyethylene glycol PAT process analytical technology QbD quality-by-design RuBisCO ribulose-1,5-bisphosphate carboxylase/oxygenase h T-helper T-DNA transfer DNA VEGF vascular endothelial growth factor VFUs vertical farming units VLPs virus-like particles |
本文献已被 ScienceDirect 等数据库收录! |
|